Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Eosinophilic pneumonias.

V Cottin1, J-F Cordier

  • 1Department of Pulmonary Medicine, and Center for Orphan Lung Diseases, Louis Pradel University Hospital, Claude Bernard University, UMR 754 INRA-ENVL-UCBL and IFR128 Biosciences, Lyon, France.

Allergy
|June 4, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Donor to recipient age matching in lung transplantation: A European experience.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2024
Same author

Outcomes of lung transplantation for pleuroparenchymal fibroelastosis: A French multicentric retrospective study.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2024
Same author

[Genetic diffuse cystic lung disease in adults].

Revue des maladies respiratoires·2023
Same author

Alpha1-antitrypsin deficiency in Greece: Focus on rare variants.

Pulmonology·2023
Same author

[Lung transplantation for systemic sclerosis-associated interstitial lung disease].

Revue des maladies respiratoires·2023
Same author

[Updated indications and contraindications in 2022 for lung transplantation in France].

Revue des maladies respiratoires·2022
Same journal

Detergent-Containing Toothpaste Decreases Esophageal Mucosal Impedance and Alters Salivary Properties in Humans.

Allergy·2026
Same journal

Global Variation in Timing of Allergenic Food Introduction for Food Allergy Prevention: An International Survey of Healthcare Professionals.

Allergy·2026
Same journal

Deficiency of Mitochondrial Fatty Acid Enzyme, CPT1A, Underlies Airway Epithelial Barrier Dysfunction in Severe Asthma.

Allergy·2026
Same journal

Surgical Management of Non-Allergic Rhinitis-An EAACI Task Force Position Paper.

Allergy·2026
Same journal

Real-World Evaluation of AI-Assisted Readout of Skin Prick Automated Test Results.

Allergy·2026
Same journal

Serotonin Degradation and Lipid Metabolism Regulate Human Tc2 Cell Effector Functions.

Allergy·2026
See all related articles

Eosinophilic pneumonias (EP) are lung diseases marked by eosinophil buildup. Corticosteroids are key treatments, but relapses are common, necessitating further investigation and management strategies.

Area of Science:

  • Pulmonology
  • Immunology
  • Infectious Diseases

Background:

  • Eosinophilic pneumonias (EP) present with diverse severity, from mild infiltrates to acute respiratory distress syndrome.
  • Peripheral blood eosinophilia or alveolar eosinophilia defines EP, though it may be absent in early stages or with corticosteroid use.

Purpose of the Study:

  • To review the causes, clinical presentations, and management of eosinophilic pneumonias.
  • To highlight the diagnostic challenges and therapeutic approaches for various EP subtypes.

Main Methods:

  • Review of literature on eosinophilic lung diseases.
  • Analysis of diagnostic criteria including blood and alveolar eosinophilia.
  • Evaluation of treatment strategies, including corticosteroids and immunosuppressants.

Related Experiment Videos

Main Results:

  • EP causes include idiopathic factors, drugs, and parasitic infections; extrathoracic manifestations suggest Churg-Strauss syndrome (CSS) or hypereosinophilic syndrome (HES).
  • Corticosteroids are the primary treatment, yielding good responses but often leading to relapses.
  • Immunosuppressants and imatinib are indicated for specific severe or myeloproliferative cases.

Conclusions:

  • Thorough investigation for underlying causes of EP is crucial.
  • While corticosteroids are effective, long-term management requires addressing potential relapses and considering advanced therapies for complex cases like CSS and HES.